Abstract

This project is part of a Blood and Marrow Transplant Clinical Research Network which is conducting multicenter clinical trials in hematopoietic stem cell transplantation. The purpose of the network is to promote the efficient comparison of novel treatment methods and management strategies of potential benefit for children and adults undergoing blood or marrow transplantation. Studies under development include a comparison of blood versus marrow stem cell transplantation. Studies under development include a comparison of blood versus marrow stem cell transplantation after marrow ablation, the development of non-myeloablative transplant regimens, and the best ways to avoid infections in transplant patients.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01HL069330-03
Application #
6657365
Study Section
Special Emphasis Panel (ZHL1-CSR-F (S1))
Program Officer
Henslee-Downey, Jean
Project Start
2001-09-30
Project End
2006-08-31
Budget Start
2003-09-01
Budget End
2004-08-31
Support Year
3
Fiscal Year
2003
Total Cost
$405,000
Indirect Cost

  Institution

Name
University of Michigan Ann Arbor
Department
Pediatrics
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109

  Publications

Kitko, Carrie L; Braun, Thomas; Couriel, Daniel R et al. (2016) Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial. Biol Blood Marrow Transplant 22:862-8
Levine, John E; Braun, Thomas M; Harris, Andrew C et al. (2015) A PROGNOSTIC SCORE FOR ACUTE GRAFT-VERSUS-HOST DISEASE BASED ON BIOMARKERS: A MULTICENTER STUDY. Lancet Haematol 2:e21-e29
Levine, John E; Braun, Thomas M; Harris, Andrew C et al. (2015) A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study. Lancet Haematol 2:e21-9
Ferrara, James L M (2008) Advances in the clinical management of GVHD. Best Pract Res Clin Haematol 21:677-82